GlassScriptPhysician profile
David J Najjar
NPI 1467668210
$1,829.35
in general payments reported to CMS, 2019-2025
27 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $307 · 2021: $329 · 2022: $204 · 2023: $232 · 2024: $336 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $549.68 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Novo Nordisk INC | $189.22 | 2020-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $130.94 | 2020-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.09 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $84.12 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.39 | 2020-2024 | Xifaxan, Trulance |
| Amgen INC. | $75.85 | 2019-2025 | Repatha |
| Pfizer INC. | $75.62 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $61.62 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $57.43 | 2020-2021 | |
| Exact Sciences Corporation | $50.75 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $43.23 | 2021 | |
| Abbott Laboratories | $41.08 | 2021-2022 | |
| Abbvie INC. | $32.38 | 2022 | |
| Verity Pharmaceuticals INC. | $30.40 | 2024 | Tlando |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.31 | 2019-2020 | |
| Astellas Pharma US INC | $25.31 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $23.13 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $22.73 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.17 | 2020 | |
| Bausch Health US, LLC | $21.20 | 2025 | Wellbutrin, Aplenzin |
| Ultragenyx Pharmaceutical INC. | $19.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.46 | 2023 | |
| Eisai INC. | $16.59 | 2020 | |
| Amarin Pharma, INC. | $12.44 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.34 | 2021 | |
| Adlon Therapeutics L.P. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Najjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.